FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  MUNDER BARBARA A							2. Issuer Name <b>and</b> Ticker or Trading Symbol Sucampo Pharmaceuticals, Inc. [ SCMP ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner				
WONDER DARDARA A															or		10% Ov	/ner	
(Last) (First) (Middle) 4520 EAST-WEST HWY, 3RD FLOOR						Date of 106/2		Transa	action (Mon	ith/D	ay/Year)		Officer below)	(give title		Other (s below)	pecify		
4520 EA	.51-WE51	HWY, 3KD FLC	_																
(Street) BETHESDA MD US 20814				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person						
BETHESDA WID US 20014												Form filed by More than One Reporting							
(City)	City) (State) (Zip)												Person						
		Tab	le I - Non	-Deriv	ative	Se	curities	Acc	quired, D	isp	osed o	f, or Be	neficial	y Owned	l				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da						Execution Date,			Transaction Disposed Code (Instr. 5)			ties Acquired (A) or I Of (D) (Instr. 3, 4 and		Beneficia Owned F	Forn		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	,	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day)	Date, T	4. Transactic Code (Inst 8)				6. Date Exercisabl Expiration Date (Month/Day/Year)			Amount of		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				C	Code	v	(A)		Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Employee Stock Option (Right to Buy)	\$5.19	03/01/2013			A		30,000		(1)	0	3/01/2023	Class A common stock	30,000	\$0	30,000	0	D		

## **Explanation of Responses:**

1. Vesting commences on June 1, 2013 in twelve equal quarterly installments.

/s/ Barbara A. Munder

03/08/2013

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.